A Freezing Protocol for Hematopoietic Stem Cells

Pavel, Petra; Laier, Sascha

doi:10.1007/978-1-4939-9574-5_14

Cited by 2 publications

(2 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After filling, bags were cryopreserved by controlled rate freezing (Kryo 550; Planer) 6 and stored in the vapor phase of LN 2 for at least 6 months. At the end of the 6 months of storage, bags were quickly thawed using a automated method as described before, 16 allowing standardized thawing times based on the filling volume.…”

Section: Cryopreservation Storage and Thawingmentioning

confidence: 99%

“…4 Cryopreservation aims to preserve the therapeutic properties of HPCs and successful cryopreservation depends on several factors such as preservation procedures, biopreservation media, freezing rates, and thawing procedures. 5,6 In particular, freezing and thawing procedures can induce cell injury by altering cellular osmosis 7,8 related to the cryoinjury mechanism (damage of cells associated with the phase changes of water in both extra-and intracellular environments at low temperatures). Despite the advent of new cryoprotectants such as trehalose, dimethyl sulfoxide (DMSO) is the most used cryoprotectant for HPC cryopreservation as it prevents cell damage due to dehydration caused by extracellular ice.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Comparison of CryoMACS Freezing Bags with Maco Biotech Freezing-Ethinyl Vinyl Acetate Bags for Hematopoietic Progenitor Cells Cryopreservation Using a CD34⁺-Enriched Product

Becherucci

Bisin

Ermini

et al. 2020

Biopreservation and Biobanking

View full text Add to dashboard Cite

Background: Hematopoietic progenitor cells (HPCs) cryopreservation have applications, especially in the autologous setting, allowing therapeutic use several years after collection. Cryopreservation aims to preserve the therapeutic properties of HPCs, and successful cryopreservation depends on several factors such as preservation procedures, biopreservation media, freezing rates, and thawing procedures. In this context, the choice of the freezing bag is critical as it provides mechanical protection during the freezing process. Since Maco Biotech Freezing-ethinyl vinyl acetate (EVA) Bags Ò are no longer available in our country, a comparative study was developed to verify bioequivalence with the Miltenyi CryoMACS Ò freezing bag. Methods: In this study, a CD34 + -enriched product was used to better reproduce HPC apheresis. Freezing bags were filled with the same volume, cryopreserved with controlled rate freezing, and stored in the vapor phase of liquid nitrogen for at least 6 months. After thawing, all bags were tested for integrity and sterility using a microbial challenge. In addition, a comparison was developed by evaluating recovery of white blood cells, mononuclear cells, lymphocytes, and CD34 + cells. Results: No significant differences between the two manufacturers' bags have been observed in terms of the evaluated parameters. Data were confirmed, even comparing bags according to filling volume. Data presented in this study support the conclusion that CryoMACS freezing bags are bioequivalent to Maco Biotech Freezing-EVA Bags for HPC cryopreservation.

show abstract

Section: Cryopreservation Storage and Thawingmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Comparison of CryoMACS Freezing Bags with Maco Biotech Freezing-Ethinyl Vinyl Acetate Bags for Hematopoietic Progenitor Cells Cryopreservation Using a CD34⁺-Enriched Product

Becherucci

Bisin

Ermini

et al. 2020

Biopreservation and Biobanking

View full text Add to dashboard Cite

show abstract

Impact of Cryopreservation and Freeze-Thawing on Therapeutic Properties of Mesenchymal Stromal/Stem Cells and Other Common Cellular Therapeutics

et al. 2022

View full text Add to dashboard Cite

Purpose of Review Cryopreservation and its associated freezing and thawing procedures–short “freeze-thawing”–are among the final steps in economically viable manufacturing and clinical application of diverse cellular therapeutics. Translation from preclinical proof-of-concept studies to larger clinical trials has indicated that these processes may potentially present an Achilles heel to optimal cell product safety and particularly efficacy in clinical trials and routine use. Recent Findings We review the current state of the literature on how cryopreservation of cellular therapies has evolved and how the application of this technique to different cell types is interlinked with their ability to engraft and function upon transfer in vivo, in particular for hematopoietic stem and progenitor cells (HSPCs), their progeny, and therapeutic cell products derived thereof. We also discuss pros and cons how this may differ for non-hematopoietic mesenchymal stromal/stem cell (MSC) therapeutics. We present different avenues that may be crucial for cell therapy optimization, both, for hematopoietic (e.g., effector, regulatory, and chimeric antigen receptor (CAR)-modified T and NK cell based products) and for non-hematopoietic products, such as MSCs and induced pluripotent stem cells (iPSCs), to achieve optimal viability, recovery, effective cell dose, and functionality of the cryorecovered cells. Summary Targeted research into optimizing the cryopreservation and freeze-thawing routines and the adjunct manufacturing process design may provide crucial advantages to increase both the safety and efficacy of cellular therapeutics in clinical use and to enable effective market deployment strategies to become economically viable and sustainable medicines.

show abstract

A Freezing Protocol for Hematopoietic Stem Cells

Cited by 2 publications

References 19 publications

Comparison of CryoMACS Freezing Bags with Maco Biotech Freezing-Ethinyl Vinyl Acetate Bags for Hematopoietic Progenitor Cells Cryopreservation Using a CD34⁺-Enriched Product

Comparison of CryoMACS Freezing Bags with Maco Biotech Freezing-Ethinyl Vinyl Acetate Bags for Hematopoietic Progenitor Cells Cryopreservation Using a CD34⁺-Enriched Product

Impact of Cryopreservation and Freeze-Thawing on Therapeutic Properties of Mesenchymal Stromal/Stem Cells and Other Common Cellular Therapeutics

Contact Info

Product

Resources

About

A Freezing Protocol for Hematopoietic Stem Cells

Cited by 2 publications

References 19 publications

Comparison of CryoMACS Freezing Bags with Maco Biotech Freezing-Ethinyl Vinyl Acetate Bags for Hematopoietic Progenitor Cells Cryopreservation Using a CD34+-Enriched Product

Comparison of CryoMACS Freezing Bags with Maco Biotech Freezing-Ethinyl Vinyl Acetate Bags for Hematopoietic Progenitor Cells Cryopreservation Using a CD34+-Enriched Product

Impact of Cryopreservation and Freeze-Thawing on Therapeutic Properties of Mesenchymal Stromal/Stem Cells and Other Common Cellular Therapeutics

Contact Info

Product

Resources

About

Comparison of CryoMACS Freezing Bags with Maco Biotech Freezing-Ethinyl Vinyl Acetate Bags for Hematopoietic Progenitor Cells Cryopreservation Using a CD34⁺-Enriched Product

Comparison of CryoMACS Freezing Bags with Maco Biotech Freezing-Ethinyl Vinyl Acetate Bags for Hematopoietic Progenitor Cells Cryopreservation Using a CD34⁺-Enriched Product